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1 Introduction 
As the emergence of value based care replaces traditional fee-for-service healthcare delivery 
models in provider settings, both public and private payers alike are turning to Evidence Based 
Medicine (EBM) to optimize reimbursement and approval decision making. EBM’s use of 
formal, analytical methods to align research evidence with medical practice has extended to 
policy makers in referencing quality and cost efficacy of potential therapeutics. As these payers 
have limited budgets, it is thus necessary to assess the allocation of resources when reviewing 
any novel health technology*, despite a common public aversity to ration patient access when 
considering therapeutic choices. Payer interest in the value of new health technologies is further 
underpinned in controlling increases in price and health consumption if decision making is 
transferred to the physician and patient.  
The field of Health Technology Assessment (HTA) concerns the investigation and 
evaluation of novel health technologies from the payer standpoint when market access requests 
are submitted for approval. HTA bodies, created in nations worldwide in the 1970s, reflected the 
emergence and advancement of biological technologies challenging conventional social, ethical, 
and political status quo (e.g. artificial organs, genetic therapy, stem cell research)1. HTA 
techniques are wide in scope in order to most-holistically examine the character of a novel health 
technology before decision making occurs. Many components exist to its multidisciplinary 
evaluation including societal, economic, and organization implications of the therapy in 
appraisal. This paper concerns the particular economic approach of HTA, Cost Effective 
                                                      
*A health technology is defined by the World Health Organization as “the application of organized knowledge and 
skills in the form of devices, medicines, vaccines, procedures and systems developed to solve a health problem and 
improve quality of lives.” 
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Analysis (CEA), that countries conduct in the decision making process as HTA bodies across 
different countries use different CEA modeling strategies in the evaluation of a novel health 
technology. By understanding how variability among CEA approach characteristics affect 
country health outcomes including health spending and health quality, we are better able to 
model the impact of critical economic decision making factors in policy guidelines of country 
health cost containment and health quality improvement. 
2 Background 
2.1 Cost Effective Analysis (CEA) 
Under HTA, the economic analysis of the technology is carried out through a cost effective 
analysis (CEA). The objective of CEA is notably summed up through a health equity lens: a 
quasi-utilitarian approach to maximize the total health of a population given limited resources. A 
CEA measures the cost per outcome unit gained of a treatment against a comparator:  
 
𝐶𝑜𝑠𝑡
𝑂𝑢𝑡𝑐𝑜𝑚𝑒
=
Δ𝐶
Δ𝐸
 (1) 
where costs are presented in monetary units and outcomes are described using quantitative non-
monetary metrics of health quality2. Most commonly, the quality-adjusted life year (QALY) has 
been recognized as an internationally used metric when referencing measurements of disease 
burden3. The QALY measures the health outcome of a patient through an index combining the 
length of life and the patient’s health related quality of life (HRQoL) based on surveys and 
various patient reported outcomes4. By standardizing such weights, payers are able to apply 
quantitative value to assess the cost-per-QALY of a given health technology, using the 
incremental cost-effectiveness ratio (ICER): 
 4 
 𝐼𝐶𝐸𝑅 =
𝐶𝑛𝑒𝑤 − 𝐶𝑜𝑙𝑑
𝐸𝑛𝑒𝑤 − 𝐸𝑜𝑙𝑑
 (2) 
which shows the quantitative benefit of the new treatment against the comparator5. Through 
measuring the cost-effectiveness of a novel technology using a ICER, health systems are able to 
recognize optimal treatments for patients and enhance the delivery of care based on therapies that 
offer maximum incremental value. CEA has potential to both identify and validate potentially 
less-complex or cheaper therapies than current standard of care, bringing novel recommendations 
to health care payers and providers. 
 
Figure 1: A cost-effectiveness matrix organizing the potential outcomes for a novel technology 
against a comparator6. Novel health treatments as points that fall past the threshold are deemed 
overall more cost-effective. 
2.2 Willingness to Pay Thresholds 
The ICER value forms the guiding metric for payers in the CEA evaluation of the novel 
technology, often times referenced against a threshold, k. This threshold value is the public 
payer’s maximum acceptable cost per QALY (or other health measure), often termed a country’s 
willingness-to-pay (WTP). On average, if the CEA value given by the ICER does not exceed the 
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threshold, the health technology has a stronger likelihood of payer approval reluctance7. This 
threshold value, however, is often times nondisclosed, as the metric grants incentives for 
pharmaceutical and biotechnology companies to tailor ICER estimates given by 
 𝑃𝑚𝑎𝑥 = 𝑃𝑜𝑙𝑑 + 𝑘∆𝐸 − ∆𝐶 (3) 
in which companies are thus able to compute the max price at which the technology will be 
approved, triggering funding. The above maximum price value would thus be a private and 
societal gain fully captured, subsequently negotiated down in the healthcare supply chain. 
 
Importantly, each country has distinct thresholds, which then influences the selection of 
therapeutics in their respective health system. There exists a threshold either explicitly stated by 
the public payer, or implicitly based on the payer’s aggregate data on historical approval price 
patterns in cases when the threshold is nondisclosed. Implicitly, it is thought that if many 
decisions are observed, it is possible to infer the cost per QALY under which approvals occur, 
thereby acting as the implicit cost-effectiveness threshold. These differences in WTP are, in 
recent years, known to correlate to the respective country’s ability-to-pay (ATP) for novel health 
technologies8, 9.  
2.3 Approaches to CEA 
Although international structures exist to country-specific pharmacoeconomic guidelines, the 
approach to CEA of national HTA bodies vary across countries. The process in which CEA 
variables are measured require considerations that are varying by nature as shown in the table 
below.  
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Approach Variables of Interest 
Units of Effectiveness 
Cost Perspectives 
Outcome Perspectives 
Choice of Comparator 
Discount Rate 
Time Horizon 
 
Figure 2: Potential variations to a CEA in terms of factors in consideration, detailing the key 
attributes to account for costs and outcomes in a cost-effective analysis 
 
These attributes are critical in an investigation and evaluation of a CEA given the different 
methods in which the same technology’s costs and outcomes can be measured. Slight variations 
in the input attributes can have significant effects on the resulting estimate of a cost-effectiveness 
ratio, particularly fragile for ICERs near a country’s WTP. 
All studies of novel health technologies conducted by national HTA bodies thus make 
clear their methodology in a CEA approach as to validate an analysis compared to another HTA 
body. Importantly, while classification of CEA approaches as guided by the International Society 
for Pharmacoeconomics and Outcomes (ISPOR) are documented across each country’s HTA 
body, no existing literature comparing approaches to health outcomes and health expenditures. 
The objective of our research was to investigate the characteristics of cost-effectiveness 
approaches for each country, identify variability across CEA approaches, and assess the 
correlation between country-specific approaches to CEA and country health and spending related 
metrics.  
By understanding the role that CEA plays in affecting healthcare spending and quality, 
we are able to gain insight into the optimal CEA modeling strategies that will guide efficient 
resource allocation of health interventions. At large, identifying CEA approaches that correlate 
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with healthcare outcomes will help inform policy makers and payers on key decisions of 
therapeutic choice to advance healthcare cost containment and quality improvement. 
 
2.4 Economic Evaluation Implications 
It is important to acknowledge the broader framework of a CEA in the HTA decision making 
process. An ICER value from a CEA alone compared against a country’s cost-effectiveness 
threshold can only be, at most, an aid in the decision making process. The economic analysis 
comprises only one component of a larger technology assessment process and thus may not be 
used as the sole factor in a complete decision-making procedure. There must be careful 
examinations surrounding the use of threshold values and deriving cost-effectiveness ratios from 
a CEA, discussed in later sections. 
 
3 Research Methodology 
3.1 Data Sources 
The data sources used in the study consists of the following: 
1. UN Human Development Index spread (2015) 
2. OECD healthcare spending (2017) 
3. WHO world health statistics (2016) 
4. Implicit and explicit ICER threshold values 
5. CEA ISPOR country-specific pharmacoeconomic guidelines  
6. IMF GDP per capita, World Economic Outlook (2018) 
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3.1.1 United Nations Human Development Report (2015)10 
The United Nations Development Programme contains reference information regarding the 
capital and development of global nations in addition to economic growth. This metric, termed 
the human development index (HDI), summarizes aggregate dimension indices serving as 
measurements for a country’s development: life expectancy index, education index, and gross 
national income (GNI) index.  
The HDI spread from the 2015 Human Development Index report thus presents an 
outline to identify varied countries of interest for further investigation in CEA. Countries for 
CEA analysis were selected from the list based on spread of development indices as well as 
feasibility for data collection based on previous data points from literature reviews. The resulting 
group of selected countries fell within very high human development (VHHD), high human 
development (HHD), and medium human development (MHD). VHHD countries consisted of 
the G7 nations: Canada, UK, US, France, Germany, Italy, Japan. HHD countries included China, 
Brazil, Mexico, and Thailand. MHD countries of analysis included South Africa and India. 
3.1.2 OECD Health Expenditure and Financing Database (2017)11 
Metrics for country health expenditure data were pulled from the Organisation for Economic Co-
operation and Development’s health spending database. The OECD defines healthcare 
expenditure as the “final consumption of health care goods and services” which includes both 
individual care consumption and collective health administration and public health spending, but 
excludes spending on investments (e.g. pharmaceutical R&D dollars and bench research). For 
each country, the aggregate health spending value was taken with respect to voluntary, out-of-
pocket, and government/compulsory expenditures.  
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3.1.3 WHO World Health Statistics12 
Life expectancy data from the World Health Organization served as a proxy for individual 
country’s health outcomes. Life expectancy as measured by the average number of years of 
lifetime survival, applied to both males and females, serves as a reflection of a country’s overall 
mortality level in its population. Driven by public health and medical interventions, the 
numerical lifespan acts as a quantitative value representing the quality of care within a country. 
Thus, mortality and health expenditure data serve as outcome variables of interest when 
examining correlations with respect to CEA approach. 
 
3.1.3 Implicit and Explicit ICER Threshold Values 
In order to locate data on country WTP, often an implicit value, an assessment of both academic 
literature and country-specific government health insurance programs allowed for source 
reliability and information cross-checking. Comparative effectiveness thresholds for all countries 
selected were gathered based on persistent, similar line-item values from secondary sources in 
academic literature and payer HTA process documents. Final data inputs relied upon an average 
of upper and lower threshold values (when available) converted to 2017 USD. 
Specifically, only the United Kingdom’s and Thailand’s HTA bodies, the National 
Institute for Health and Care Excellence (NICE) and the Health Intervention and Technology 
Assessment Program (HITAP) respectively, explicitly mention a threshold value used to guide 
decision making. These threshold values were sourced directly from online HTA website 
literature for both the two countries. The remaining countries do not delineate set values for a 
threshold on official HTA-related released literature; thus requiring further investigation into 
historic patterns of approval prices to arrive at an implicit WTP threshold. Implicit country 
threshold values were thus cross checked on multiple sources of academic literature and country-
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specific health technology economic assessment bodies to derive repeatable estimates. The 
articles used are cited in the threshold column of Figure 3 below in the results section. Of 
particular note is the usage of Wood’s approach13 to derive threshold estimates for less 
developed nations without well-established HTA bodies that lacked detailed cost-effectiveness 
analysis explanations. Woods creates a predictive model extrapolating from the United Kingdom 
cost-effectiveness threshold to estimate opportunity-cost-based WTP for low/middle income 
countries, for which there had previously been no values available.  
3.1.4 CEA ISPOR Country-specific Pharmacoeconomic Guidelines14 
The International Society for Pharmacoeconomics and Outcomes (ISPOR) specializes in health 
economics & outcomes research (HEOR) and includes data on variables related to cost-
effectiveness approaches in assessing a novel technology. ISPOR’s data system includes 
information on guidelines used as an “analytical tool used with increasing frequency to assist 
decision making in the financing and management of pharmaceutical products.” These guidelines 
for each selected country serve as the regression inputs for comparison against health outcomes 
of interest. In situations where CEA approach data was not available through ISPOR’s 
pharmacoeconomic guidelines, academic literature was referenced for specific data points. 
3.1.5 IMF GDP Per Capita Prices, World Economic Outlook (2018)15 
In order to account for the effect that inherent country development holds on the country’s ATP, 
GDP per capita and population statistics were gathered from the International Monetary Fund’s 
World Economic Outlook report for each selected country. The regression is controlled for these 
other, non-CEA approach-related factors that may impact healthcare spending, effectively 
isolating the interaction of CEA attributes on outcomes of interest.   
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3.2 First Round Regression 
To examine the role of WTP threshold data in a country’s HTA, univariate linear regression 
models of WTP were tested against outcomes of interest. Country WTP threshold data is noted to 
proportionally relate to health expenditure and health quality. By determining the correlation 
between WTP threshold data and regression outcomes, we are able to determine if such 
relational factors exist and maintain WTP threshold data in further regression analysis as a 
controlling variable in later regressions with all CEA approach characters as explanatory 
variables of interest. This controls for the influence of the threshold variable on outcomes of 
interest, isolating potential effect of CEA attributes on outcomes further. 
Upon confirming WTP relationship, multivariate least squares regression were run on 
country approach factors against outcomes of interest. This phase two of first round regression 
gives insight into the strength of the correlation between CEA approach variables and outcomes, 
modeling both continuous and dummy variable effects on country health expenditure and life 
expectancy. 
3.3 Second Round Regression 
 
In order to test conditions of correlation between CEA attributes and outcome variables of 
interest, we construct various multiple regression linear models with stepwise ANOVA trials. To 
control for other country-specific factors, we include variables with significant effect on 
outcomes of interest from first round regressions. Through stepwise analysis, multivariate model 
selection based on a minimum Bayesian Information Criterion (BIC) stopping rule determine 
CEA attribute effect on outcomes of interest. The stepwise regression fit serves to maximize the 
likelihood function, L(), through estimating the variable parameters, , that maximize the 
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probability density functions at the observed data points. The BIC perspective to assess stepwise 
model fit is defined as: 
 𝐵𝐼𝐶 =  −2𝐿𝑜𝑔(𝐿()) + 𝑘𝑙𝑛(𝑛) (4) 
where k is the number of estimated parameters and n is the number of model observations in 
reframing likelihood maximization as minimizing negative log-likelihood. Thus a BIC stepwise 
fit maximizes parameter fit of potential multivariable effects on outcomes of interest. 
 
4 Results 
4.1 Threshold Values 
 
Both explicit and implicit WTP values were collected for selected countries through identifying 
data from each country’s established public health economics and outcomes research (HEOR) or 
HTA body. Final ICER thresholds were based on selected upper and lower threshold values, 
converted to USD and adjusted for inflation to 2017 prices. Explicit thresholds, consisting of 
only the United Kingdom and Thailand, were gathered from public government disclosures. 
Implicit thresholds determined through literature reviews on academic journals and government 
databases formed the upper and lower threshold bounds, of which the mean formed the threshold 
value.  The thresholds used in the study are listed in Figure 3. 
 
Table 1 Established ICER Thresholds by Country     
Country HEOR or HTA Body HDI T-L USD T-U USD 
ICER 
Threshold 
Canada 
Canadian Agency for Drugs 
and Technology in Health 
(CADTH) 
Very 
High $38,199   $38,19916 
UK 
National Institute for Health 
and Care Excellence (NICE) 
Very 
High $26,576 $39,864 $33,22017 
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US 
Agency for Healthcare 
Research and Quality (AHRQ) 
Very 
High $50,000 $150,000 $100,00018, 19 
France 
Haute Autorité de Santé 
(HAS) 
Very 
High $35,263   $35,26320, 21 
Germany 
Institute for Quality and 
Efficiency in Health Care 
(IQWiG) 
Very 
High $133,881 $5,228 $69,55422 
Italy 
Italian National Health 
Services (NHS) 
Very 
High $29,363   $29,36323 
Japan 
Central Social Insurance 
Medical Council 
Very 
High $45,259 $54,311 $49,78524 
China 
China Ministry of Health 
(MoH) High $4,210 $5,814 $5,01225 
Brazil Brazil Ministry of Health High $2,153 $23,016 $12,58526 
Mexico 
Mexico General Health 
Council High $24,083 $6,953 $15,51813 
Thailand 
Health Intervention and 
Technology Assessment 
Program (HITAP) High $4,826   $4,82627 
S. Africa 
Republic of South Africa 
Department of Health Medium $1,211 $4,857 $3,03413 
India 
Medical Technology 
Assessment Board (MTAB) Medium $118 $793 $45613 
 
Figure 3: List of collected threshold values by country in inflation adjusted 2018 USD prices. 
 
 
 
4.2 CEA Approaches 
 
The following table documents the CEA approach of each country based on Figure 2’s list of 
attributes on cost-effective variables. Attributes consist of both categorical and numeric data, 
referring to the methods and perspectives taken in the CEA calculations when assessing value of 
a novel health technology. 
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4.3 First Round Regressions 
Least squares regression were run for all variables of interest on two principal health outcomes: 
health expenditures per capita and life expectancy from the country level of observation. The 
resulting coefficient estimates from multivariate models are shown below.  
Least Squares Regression on Country Life Expectancy 
 
Figure 5: All explanatory variables of interest tested for effect on life expectancy. GDPPC 
represents the per capita gross domestic product of the country. All dummy variables modeled in 
the analysis took either yes or no values as input, with baseline metrics (‘Variable[No]’) listed 
above representing the lack of variable presence in the economic analysis.  
A least squares fit of variable country CEA approaches on country mortality rates, described by 
the life expectancy proxy, showed the above results. The table highlights the GDP per capita of 
the nation as the only statistically significant variable contributing to the health outcomes of the 
country at the 5% level of rigor; all other CEA approach variables are not statistically significant 
with a p-value > 0.05. However, multiple remaining variables hold close proximity to a 0.05 
threshold with many p-values ranging between 0.05 and 0.15, with WTP, third party costs, direct 
& caretaker outcomes, societal outcomes, and QALYs as marginally significant with statistical 
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significance at the 10% level. This poses near significant variables that should be investigated 
more closely in stepwise second round ANOVA regressions. 
According to the data table, GDPPC serves as the best predictor of life expectancy, given 
that it was used as a controlling factor for the country’s development status. The predictor thus 
illustrates that while approach characteristics vary across all countries selected in the analysis, 
ultimate health outcomes are not dictated by CEA approach factors but rather in the broader 
context of country development. No clear correlation exists between country CEA approach and 
life expectancy, signaling that variability among factors in economic analysis calculations do not 
significantly correlate with a country’s health outcomes.  
Least Squares Regression on Country Health Expenditure 
 
 
Figure 6: All explanatory variables of interest tested for effect on health expenditure 
The least squares fit of CEA approach variables on country health expenditure show minimal 
correlation with no variables holding statistically significant effect on per capita health 
expenditures. The explanatory variables used in the analysis include all economic factor 
approaches in cost-effectiveness while removing country population as the health expenditure 
outcome accounts for per capita effect. Given no p-value < 0.05, the model results suggest that 
CEA approach factors do not significantly correlate with health expenditure. Both least square 
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regression fits serve to validate that heterogeneity indeed exists within country CEA approaches 
with minimal correlation to health outcomes. 
 
4.4 Second Round Regressions 
The second analysis conducted on the dataset relied on a multivariate stepwise ANOVA study 
with a minimum BIC approach set on a forward direction. This stepwise regression model 
functions as a method for identification of the optimal parameters in each regression, maximizing 
the likelihood function given in equation 4. 
Stepwise Regression on Country Life Expectancy 
 
Figure 7: A minimum BIC stepwise regression of multivariate character on life expectancy 
The maximization of probability density for parameter fit given by the stepwise analysis show 
that all CEA approach variables fall within the optimal model. P-values of explanatory variables 
show distinct differences in strength from least squares regression but all fall within a general 
range of 0.05 to 0.30. Such resulting values demonstrate that we are unable to form a correlation 
of CEA approach variables on country life expectancy with 95% confidence. Rather, a lower 
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confidence level assumed in the model is taken in stepwise regression with greater density 
distribution fit. 
 
Stepwise Regression on Country Health Expenditure 
 
Figure 8: A minimum BIC stepwise regression of multivariate character on health expenditure 
An evaluation of CEA approach on country health expenditures per capita using a stepwise fit 
model shows statistically significant fit of four particular characters noted above in Figure 8, 
with p-values < 0.10. According to the forward minimum BIC stepwise regression, testing 
combinations of parameters resulted in the best correlation fit including the continuous variables 
WTP, cost and outcomes discount rate, GDPPC and the dummy variable of societal cost 
inclusion. The stepwise model thus illustrates the correlative effect of specific explanatory 
variables on country health expenditures, with GDPPC being the only statistically significant 
input under 95% confidence interval assumptions. 
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4.5 Discussion 
The motivation behind the research question presented in this paper relies on the heterogeneous 
approach factors in a cost-effectiveness economic analysis of each country. Through literature 
reviews and pulling metrics from datasets, we were able to run multivariate regressional analyses 
testing correlative strength of CEA approach characteristics. By modeling correlations of country 
economic approach variables with health related outcomes of interest, the strength of each 
variable’s effect on country health outcomes is measured. It was hypothesized that CEA 
approach variability would demonstrate correlation to health outcomes in line with different 
economic perspectives in an HTA corresponding to different health outcomes. To control for 
tests of interest with CEA approach and health outcome variables in addition to country-specific 
economic character, univariate fit lines constructed for WTP on outcome variables demonstrated 
valid inclusion of a country’s threshold value in the CEA approach regression analysis. 
 Results from the first round multivariate regression tests show minimal variable 
correlation with outcomes of interest. Using a p-value threshold of 0.05, country GDP per capita 
is the only statistically significant value to correlate with life expectancy. The basis behind the 
correlation can be explained through country development status where a higher GDPPC 
signifies a more overall developed country, including its healthcare system thus correlating with 
quality of healthcare given by the life expectancy proxy. A similar model applied to health 
expenditure shows minimal correlation, with no variables in the analysis showing statistically 
significant p-values. These results from first round suggest that while CEA approach variables 
are heterogenous across countries, they hold no significant effect on influencing country health 
outcomes.  
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 A second round multivariate regression using a stepwise fitting method maximized the 
likelihood function, L(),and formed correlative fits based on optimization models. The stepwise 
fit against country life expectancy registered all CEA approach variables in the model, fitting all 
economic perspective variation to explain quality of healthcare. This direct contrast to the first 
round regression in which only GDPPC was significantly correlated with life expectancy 
demonstrate the need for further statistical examinations and methods to pinpoint effect. 
Similarly, a contrast was observed to first round regressions in a fit on health expenditure in 
which key variables held statistical significance whereas no correlation was observed in the least 
squares model. 
Nonetheless, as the stepwise regression holds a lower confidence interval of significance 
and includes variables with p-values of lower strength than the least squares multivariate fit, the 
results of first round regression hold greater precision and acts as a more robust analysis. Thus 
we infer from our data reports that while stepwise regression contributes a separate perspective 
in a cost-effectiveness approach model, the least squares models holds greater probability of 
explanation in which GDPPC correlates with country life expectancy and no approach variation 
correlate with country health expenditure. 
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4.6 Limitations 
The study faces limitations in scope due to data-collection constraints. As WTP threshold metrics 
are non-disclosed points kept within government records, it is difficult to pinpoint precision 
behind the values used in the analysis. A general scope of public literature is not as accurate as 
primary research from source officials, requiring broader research methods and further direct 
investigation with government data reports. Additionally, similar issues arose in data collection 
of cost-effectiveness approach variables as report information is not clearly delineated across 
country government reports. The variables used in the analysis consisted of all heterogenous 
approach variations despite some similarities across country economic approaches. Other 
variables to control for country-specific characteristics in affecting outcomes of interest may be 
required as the usage of GDPPC and population size are only nominally correlative with health 
expenditure and life expectancy.  
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5 Summary and Recommendations 
5.1 Summary 
Through an investigation of country specific cost-effective approaches, the study aimed to derive 
correlations between variability across country CEA approach attributes and health outcomes of 
interest. A least squares regression supported with a stepwise multivariate method showed that 
while heterogeneity exists among a government’s HTA economic analysis, CEA approach 
differences do not significantly correlate directly with country health expenditure nor quality of 
care delivered. Additionally, the study was able to successfully characterize country WTP 
thresholds and correlate the threshold values, both implicit and explicit, with outcomes of 
interest. It was determined that both these threshold values exist for each country and such values 
held relationships with country health outcomes. Overall, despite proper characterization of 
country WTP and CEA approach attributes across a country’s HTA or Health Economics & 
Outcomes Research (HEOR) body, there are no statistically significant effects of a variable in 
CEA approach on country related health outcomes. 
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5.2 Recommendations for Further Studies  
In further investigation of HTA economic approach, two primary recommendations are offered: 
First, it is recommended that economic approach characteristics are broken down further 
across countries to capture greater perspective variation. While the current study captured 
various categorical and continuous variables across government systems, breakdown of 
economic analysis approaches can be categorized into greater segments. Through assessing 
greater variability across country methods, one is able to add additional explanatory effect into a 
regression analysis and capture greater detail in country differences to CEA approach. 
  Second, emphasis must be placed on this study as a correlative analysis and not causal. It 
is suggested that in order to study causal links of a CEA approach on health outcomes of interest, 
one must track cross-sectional time points by tracking data over multiple years to account for 
how a country’s change in CEA approach affects its respective health system. More data points 
across a greater number of countries may be utilized in a future analysis to expand the 
explanatory strength of the regression tests. Through incorporating further statistical models on 
both a greater n and a causal analysis, researchers may be able to derive optimal CEA approach 
links to health outcomes. 
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